XWARURT
Market cap31mUSD
Dec 23, Last price
92.00PLN
1D
4.07%
1Q
-3.77%
IPO
-6.12%
Name
Urteste SA
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-6m
L+37.59%
CFO
-5m
L+40.31%
Profile
Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, stomach, lung, oesophagus, ovary, endometrium, blood, breast, and nervous system cancer. The company was incorporated in 2021 and is based in Gdansk, Poland.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 3 | ||||
Cost of revenue | 6,034 | 2,879 | 2,918 | ||
Unusual Expense (Income) | |||||
NOPBT | (6,034) | (2,876) | (2,918) | ||
NOPBT Margin | |||||
Operating Taxes | 162 | (1) | |||
Tax Rate | |||||
NOPAT | (6,196) | (2,876) | (2,918) | ||
Net income | (5,586) 37.59% | (4,060) | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 27,708 | 11,772 | |||
BB yield | -19.66% | -11.67% | |||
| Debt | |||||
Debt current | 315 | 124 | 117 | ||
Long-term debt | 939 | 946 | 593 | ||
Deferred revenue | |||||
Other long-term liabilities | 100 | ||||
Net debt | (23,396) | (2,384) | (7,843) | ||
| Cash flow | |||||
Cash from operating activities | (5,322) | (3,793) | |||
CAPEX | (1,743) | (1,193) | |||
Cash from investing activities | (24,400) | (1,193) | |||
Cash from financing activities | 27,427 | (113) | 11,335 | ||
FCF | (7,301) | (4,108) | (3,385) | ||
| Balance | |||||
Cash | 24,650 | 3,434 | 8,533 | ||
Long term investments | 20 | 20 | |||
Excess cash | 24,650 | 3,454 | 8,553 | ||
Stockholders' equity | (6,432) | (4,932) | 1,989 | ||
Invested Capital | 34,802 | 11,137 | 7,894 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 1,293 | 1,135 | 1,052 | ||
Price | 109.00 37.97% | 79.00 -17.62% | 95.90 | ||
Market cap | 140,943 57.16% | 89,679 -11.11% | 100,885 | ||
EV | 117,547 | 87,295 | 93,042 | ||
EBITDA | (5,258) | (2,439) | (2,898) | ||
EV/EBITDA | |||||
Interest | 570 | 51 | |||
Interest/NOPBT | |||||